IBI 363
Alternative Names: IBI-363Latest Information Update: 17 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-2 expression stimulants; Interleukin-2 replacements; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Malignant melanoma
- Phase I Lymphoma
- Clinical Phase Unknown Cancer
Most Recent Events
- 14 Jun 2024 Updated efficacy and adverse event data from a phase Ia/Ib trial in Solid tumours released by Innovent Biologics
- 02 Jun 2024 Efficacy and adverse events data from the phase I trial in Solid tumours was released by Innovent Biologics
- 31 May 2024 Updated efficacy data from a phase Ia/Ib trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)